Blog
Unit 3 Micro: Glaxo SmithKline fined $3 billion for off-label marketing
3rd July 2012
The scale of the fine is staggering, Glaxo SmithKline has been found guilty of off-label marketing - an illegal strategy - GSK targeted the antidepressant Paxil at patients under age 18 when it was approved only for adults, and promoted the drug Wellbutrin for uses it was not approved for, including weight loss and treatment of sexual dysfunction
This is corporate irresponsibility on a grand scale as this new report makes clear.
Guardian: GlaxoSmithKline fined $3bn for healthcare fraud
Daily Mail: GlaxoSmithKline to pay $3billion fine after pleading guilty to healthcare fraud - the biggest in U.S. history
News video:
See also
Geoff Riley
Geoff Riley FRSA has been teaching Economics for over thirty years. He has over twenty years experience as Head of Economics at leading schools. He writes extensively and is a contributor and presenter on CPD conferences in the UK and overseas.